Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Expert Perspectives on Integrating Immuno-Oncology Therapeutics Into the Management of Metastatic Triple-Negative Breast Cancer
  • CME
  • CE

Sarah Donahue, MPH, NP
David B. Page, MD
Hope S. Rugo, MD
Peter Schmid, MD, PhD, FRCP
Released: May 14, 2020
Back Next


  1. US Food and Drug Administration. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative. Accessed May 8, 2020.
  2. US Food and Drug Administration VENTANA PD-L1 (SP142) assay premarket approval (PMA). Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160002S009. Accessed May 8, 2020.
  3. Rugo HS, Loi S, Adams S, et al. Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (MTNBC): post-hoc analysis of IMpassion130. Program and abstracts of the 2019 ESMO Congress; September 27 - October 1, 2019; Barcelona, Spain. Abstract LBA20.
  4. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108-2121.
  5. Schmid P, Adams S, Rugo HS, et al. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). Program and abstracts of the 2019 American Society of Clinical Oncology annual meeting; May 31 - June 4, 2019; Chicago, Illinois. Abstract 1003.
  6. ClinicalTrials.gov. Study of pembrolizumab (MK-3475) plus chemotherapy vs. placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple negative breast cancer (MK-3475-355/KEYNOTE-355). Available at: https://clinicaltrials.gov/ct2/show/NCT02819518. Accessed May 8, 2020.
  7. ClinicalTrials.gov. A study of the efficacy and safety of atezolizumab plus chemotherapy for patients with early relapsing recurrent triple-negative breast cancer (IMpassion132). Available at: https://www.clinicaltrials.gov/ct2/show/NCT03371017. Accessed May 8, 2020.
  8. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714-1768.
  9. Sacituzumab govitecan-hziy [package insert]. Morris Plains, NJ: Immunomedics, Inc; 2020.
  10. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741-751.
  11. ClinicalTrials.gov. ASCENT-study of sacituzumab govitecan in refractory/relapsed triple-negative breast cancer (ASCENT). Available at: https://clinicaltrials.gov/ct2/show/NCT02574455. Accessed May 5, 2020.
  12. US Food and Drug Administration. FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2-positive-breast-cancer. Accessed May 5, 2020.
  13. ClinicalTrials.gov. Trastuzumab deruxtecan (DS-8201a) versus investigator's choice for HER2-low breast cancer that has spread or cannot be surgically removed [DESTINY-Breast04]. Available at: https://clinicaltrials.gov/ct2/show/NCT03734029. Accessed May 8, 2020.
  14. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-4434.
  15. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164-172.
  16. Schmid P, Park YH, Ferreira M, et al. KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early triple-negative breast cancer: Pathologic complete response in key subgroups and by treatment exposure, residual cancer burden, and breast-conserving surgery. Program and abstracts of the 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. Abstract GS3-03.
  17. Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Program and abstracts of the 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. Abstract GS3-04.
  18. Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:397-404.
  19. Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34:2460-2467.
  20. Page DB, Bear H, Prabhakaran S, et al. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. NPJ Breast Cancer. 2019;5:34.
  21. Yan Y, Kumar AB, Finnes H, et al. Combining immune checkpoint inhibitors with conventional cancer therapy. Front Immunol. 2018;9:1739.
  22. Gatti-Mays ME, Balko JM, Gameiro SF, et al. If we build it they will come: targeting the immune response to breast cancer. NPJ Breast Cancer. 2019;5:37.
  23. Opzoomr JW, Sosnowska D, Anstee JE, et al. Cytotoxic chemotherapy as an immune stimulus: a molecular perspective on turning up the immunological heat on cancer. Front Immunol. 2019;10:1654.
  24. Page DB, Chun B, Pucilowska J, et al. Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC). Program and abstracts of the 2019 American Society of Clinical Oncology annual meeting; May 31 - June 4, 2019; Chicago, Illinois. Abstract 1015.
  25. Kim I, Sanchez K, McArthur HL, et al. Immunotherapy in triple-negative breast cancer: present and future. Curr Breast Cancer Rep. 2019;11:259-271.
  26. ClinicalTrials.gov. Pembrolizumab and enobosarm in treating patients with androgen receptor positive metastatic triple negative breast cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02971761?term=NCT02971761&draw=2&rank=1. Accessed May 8, 2020.
  27. ClinicalTrials.gov. Nivolumab, ipilimumab, and bicalutamide in human epidermal growth factor (HER) 2 negative breast cancer patients. Available at: https://clinicaltrials.gov/ct2/show/NCT03650894?term=NCT03650894&draw=2&rank=1. Accessed May 8, 2020.
  28. McCann KE, Hurvitz SA. Advances in the use of PARP inhibitor therapy for breast cancer. Drugs Context. 2018;7:212540.
  29. Olaparib [package insert]. Gaithersburg, MD: AstraZeneca Pharmaceuticals LP; 2019.
  30. Talazoparib [package insert]. San Francisco, CA: Pfizer, Inc; 2020.
  31. Ding L, Kim HJ, Wang Q, et al. PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep. 2018;25:2972-2980.
  32. Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132-1140.
  33. Walle T, Monge RM, Cerwenka A, et al. Radiation effects on antitumor immune responses: current perspectives and challenges. Ther Adv Med Oncol. 2018;10:1758834017742575.
  34. Liu ZB, Zhang L, Bian J, et al. Combination strategies of checkpoint immunotherapy in metastatic breast cancer. Onco Targets Ther. 2020;13:2657-2666.
Back Next
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?